These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10282112)

  • 1. FDA's conduct, review, and evaluation of inspections of clinical investigators.
    Turner G; Lisook AB; Delman DP
    Drug Inf J; 1987; 21(2):117-25. PubMed ID: 10282112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interrelationship of sponsors, clinical investigators, and institutional review boards.
    Kirsch TJ
    Drug Inf J; 1987; 21(2):127-31. PubMed ID: 10282113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA audits of clinical studies: policy and procedure.
    Lisook AB
    J Clin Pharmacol; 1990 Apr; 30(4):296-302. PubMed ID: 2341577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory overview: protection of human subjects--IRBS and informed consent.
    Nightingale SL
    Drug Inf J; 1987; 21(2):109-15. PubMed ID: 10282111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advisory committees; OTC Drugs Advisory Committee; establishment--FDA. Final rule.
    Fed Regist; 1991 Sep; 56(185):48103-4. PubMed ID: 10114368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research Deviations in FDA-Regulated Clinical Trials: A Cross-Sectional Analysis of FDA Inspection Citations.
    Garmendia CA; Epnere K; Bhansali N
    Ther Innov Regul Sci; 2018 Sep; 52(5):579-591. PubMed ID: 29714561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA's Bioresearch Monitoring Program.
    Kelsey FO
    Methods Find Exp Clin Pharmacol; 1982; 4(7):503-8. PubMed ID: 7169836
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA's proposed rules for institutional review boards.
    Hendrix TR
    J Med Educ; 1979 Dec; 54(12):961-3. PubMed ID: 513103
    [No Abstract]   [Full Text] [Related]  

  • 9. U.S. Food and Drug Administration inspections of clinical investigators: overview of results from 1977 to 2009.
    Morgan-Linnell SK; Stewart DJ; Kurzrock R
    Clin Cancer Res; 2014 Jul; 20(13):3364-70. PubMed ID: 24737548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA overview and current challenges in regulation of human subject protection. Food and Drug Administration.
    Nightingale SL
    J Int Assoc Physicians AIDS Care; 1997 Jan; 3(1):24-6. PubMed ID: 11363959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Court is asked to invalidate the Food and Drug Administration's (FDA's) "pediatric rule".
    Maloney DM
    Hum Res Rep; 2002 Dec; 17(12):8. PubMed ID: 12731500
    [No Abstract]   [Full Text] [Related]  

  • 13. Medical devices; procedures for investigational device exemptions--Food and Drug Administration. Final rule.
    Fed Regist; 1980 Jan; 45(13):3732-59. PubMed ID: 10248822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.
    Lindblad AS; Manukyan Z; Purohit-Sheth T; Gensler G; Okwesili P; Meeker-O'Connell A; Ball L; Marler JR
    Clin Trials; 2014 Apr; 11(2):205-17. PubMed ID: 24296321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A program to provide regulatory support for investigator-initiated clinical research.
    Arbit HM; Paller MS
    Acad Med; 2006 Feb; 81(2):146-53. PubMed ID: 16436575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The drug approval process and the information it provides.
    Myers A; Moore SR
    Drug Intell Clin Pharm; 1987 Oct; 21(10):821-6. PubMed ID: 3322757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Institutional Review Board policies and procedures provide protection for human research subjects and hospitals.
    Reynolds MB
    Health Care Law Newsl; 1992 Sep; 7(9):7-11. PubMed ID: 10123075
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA's new drug evaluation process: a general overview.
    Walters PG
    J Public Health Dent; 1992; 52(6):333-7. PubMed ID: 1432918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The IRB as deputy sheriff: proposed FDA regulation of the institutional review board.
    Huff TA
    Clin Res; 1979 Apr; 27(2):103-8. PubMed ID: 10241072
    [No Abstract]   [Full Text] [Related]  

  • 20. Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world.
    Caldron PH; Gavrilova SI; Kropf S
    Drug Des Devel Ther; 2012; 6():53-60. PubMed ID: 22563236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.